Sensitizing Staphylococcus aureus to antibacterial agents by decoding and blocking the lipid flippase MprF

Abstract

The pandemic of antibiotic resistance represents a major human health threat demanding new antimicrobial strategies. MprF is the synthase and flippase of the phospholipid lysyl-phosphatidylglycerol that increases virulence and resistance of methicillin-resistant Staphylococcus aureus (MRSA) and other pathogens to cationic host defense peptides and antibiotics. With the aim to design MprF inhibitors that could sensitize MRSA to antimicrobial agents and support the clearance of staphylococcal infections with minimal selection pressure, we developed MprF-targeting monoclonal antibodies, which bound and blocked the MprF flippase subunit. Antibody M-C7.1 targeted a specific loop in the flippase domain that proved to be exposed at both sides of the bacterial membrane, thereby enhancing the mechanistic understanding of bacterial lipid translocation. M-C7.1 rendered MRSA susceptible to host antimicrobial peptides and antibiotics such as daptomycin, and it impaired MRSA survival in human phagocytes. Thus, MprF inhibitors are recommended for new anti-virulence approaches against MRSA and other bacterial pathogens.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files.

Article and author information

Author details

  1. Christoph Josef Slavetinsky

    Pediatric Gastroenterology and Hepatology, Eberhard Karls University Tübingen, Tübingen, Germany
    For correspondence
    christoph.slavetinsky@med.uni-tuebingen.de
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-5576-5906
  2. Janna Nadine Hauser

    Department of Infection Biology, Eberhard Karls University Tübingen, Tübingen, Germany
    Competing interests
    No competing interests declared.
  3. Cordula Gekeler

    Department of Infection Biology, Eberhard Karls University Tübingen, Tübingen, Germany
    Competing interests
    No competing interests declared.
  4. Jessica Slavetinsky

    Department of Infection Biology, Eberhard Karls University Tübingen, Tübingen, Germany
    Competing interests
    No competing interests declared.
  5. André Geyer

    Department of Infection Biology, Eberhard Karls University Tübingen, Tübingen, Germany
    Competing interests
    No competing interests declared.
  6. Alexandra Kraus

    MorphoSys AG, Planegg, Germany
    Competing interests
    Alexandra Kraus, Antibodies disclosed in the manuscript are part of patent Anti-staphylococcal antibodies" (US9873733B2 / EP2935324B1).
  7. Doris Heilingbrunner

    MorphoSys AG, Planegg, Germany
    Competing interests
    No competing interests declared.
  8. Samuel Wagner

    Cluster of Excellence 'Controlling Microbes to Fight Infections', University of Tübingen, Tübingen, Germany
    Competing interests
    No competing interests declared.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1808-3556
  9. Michael Tesar

    MorphoSys AG, Planegg, Germany
    Competing interests
    Michael Tesar, Antibodies disclosed in the manuscript are part of patent Anti-staphylococcal antibodies" (US9873733B2 / EP2935324B1).
  10. Bernhard Krismer

    Department of Infection Biology, Eberhard Karls University Tübingen, Tübingen, Germany
    Competing interests
    No competing interests declared.
  11. Sebastian Kuhn

    Department of Infection Biology, Eberhard Karls University Tübingen, Tübingen, Germany
    Competing interests
    No competing interests declared.
  12. Christoph M Ernst

    Department of Molecular Biology and Center for Computational and Integrative Biology, Broad Institute, Cambridge, United States
    For correspondence
    cmernst@broadinstitute.org
    Competing interests
    Christoph M Ernst, Antibodies disclosed in the manuscript are part of patent Anti-staphylococcal antibodies" (US9873733B2 / EP2935324B1).
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5575-1325
  13. Andreas Peschel

    Department of Infection Biology, Eberhard Karls University Tübingen, Tuebingen, Germany
    Competing interests
    Andreas Peschel, Antibodies disclosed in the manuscript are part of patent Anti-staphylococcal antibodies" (US9873733B2 / EP2935324B1).

Funding

Deutsche Forschungsgemeinschaft (EXC-2124/1-09.001_0)

  • Christoph Josef Slavetinsky

Deutsche Forschungsgemeinschaft (EXC-2124/1-09.010_0)

  • Christoph Josef Slavetinsky

Deutsches Zentrum für Infektionsforschung (TTU 08.806)

  • Christoph Josef Slavetinsky

Deutsches Zentrum für Infektionsforschung (TTU 08.806)

  • Andreas Peschel

Deutsche Forschungsgemeinschaft (SFB 766/1-3,TP A08)

  • Andreas Peschel

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Copyright

© 2022, Slavetinsky et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 2,525
    views
  • 456
    downloads
  • 32
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Christoph Josef Slavetinsky
  2. Janna Nadine Hauser
  3. Cordula Gekeler
  4. Jessica Slavetinsky
  5. André Geyer
  6. Alexandra Kraus
  7. Doris Heilingbrunner
  8. Samuel Wagner
  9. Michael Tesar
  10. Bernhard Krismer
  11. Sebastian Kuhn
  12. Christoph M Ernst
  13. Andreas Peschel
(2022)
Sensitizing Staphylococcus aureus to antibacterial agents by decoding and blocking the lipid flippase MprF
eLife 11:e66376.
https://doi.org/10.7554/eLife.66376

Share this article

https://doi.org/10.7554/eLife.66376

Further reading

    1. Genetics and Genomics
    2. Microbiology and Infectious Disease
    Louna Fruchard, Anamaria Babosan ... Zeynep Baharoglu
    Research Article

    Tgt is the enzyme modifying the guanine (G) in tRNAs with GUN anticodon to queuosine (Q). tgt is required for optimal growth of Vibrio cholerae in the presence of sub-lethal aminoglycoside concentrations. We further explored here the role of the Q34 in the efficiency of codon decoding upon tobramycin exposure. We characterized its impact on the overall bacterial proteome, and elucidated the molecular mechanisms underlying the effects of Q34 modification in antibiotic translational stress response. Using molecular reporters, we showed that Q34 impacts the efficiency of decoding at tyrosine TAT and TAC codons. Proteomics analyses revealed that the anti-SoxR factor RsxA is better translated in the absence of tgt. RsxA displays a codon bias toward tyrosine TAT and overabundance of RsxA leads to decreased expression of genes belonging to SoxR oxidative stress regulon. We also identified conditions that regulate tgt expression. We propose that regulation of Q34 modification in response to environmental cues leads to translational reprogramming of transcripts bearing a biased tyrosine codon usage. In silico analysis further identified candidate genes which could be subject to such translational regulation, among which DNA repair factors. Such transcripts, fitting the definition of modification tunable transcripts, are central in the bacterial response to antibiotics.

    1. Microbiology and Infectious Disease
    Nicolas Flaugnatti, Loriane Bader ... Melanie Blokesch
    Research Article

    The type VI secretion system (T6SS) is a sophisticated, contact-dependent nanomachine involved in interbacterial competition. To function effectively, the T6SS must penetrate the membranes of both attacker and target bacteria. Structures associated with the cell envelope, like polysaccharides chains, can therefore introduce spatial separation and steric hindrance, potentially affecting the efficacy of the T6SS. In this study, we examined how the capsular polysaccharide (CPS) of Acinetobacter baumannii affects T6SS's antibacterial function. Our findings show that the CPS confers resistance against T6SS-mediated assaults from rival bacteria. Notably, under typical growth conditions, the presence of the surface-bound capsule also reduces the efficacy of the bacterium's own T6SS. This T6SS impairment is further enhanced when CPS is overproduced due to genetic modifications or antibiotic treatment. Furthermore, we demonstrate that the bacterium adjusts the level of the T6SS inner tube protein Hcp according to its secretion capacity, by initiating a degradation process involving the ClpXP protease. Collectively, our findings contribute to a better understanding of the dynamic relationship between T6SS and CPS and how they respond swiftly to environmental challenges.